Q-omics provides the consensus-scored DYNLL1P5 profile across patient tissues and cancer cell-line models. DYNLL1P5 expression is associated with patient survival in 10 of 34 cancer types, with the highest sampling consensus in UCS. Among the 18 cancer types available for tumor–normal comparison, DYNLL1P5 is differentially expressed in 1, with the highest sampling consensus in STAD. Additionally, DYNLL1P5 RNA expression shows 4,700 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight UCS, and STAD as cancer lineages where DYNLL1P5 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for DYNLL1P5 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes DYNLL1P5 survival associations across molecular data types. DYNLL1P5 RNA expression shows survival associations in the most cancer types (10). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible DYNLL1P5 RNA expression–survival associations across cancer types. High DYNLL1P5 expression shows unfavorable associations in UCS, THCA, HNSC, LGG, STAD and TGCT. The UCS Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify UCS as the clearest survival context for DYNLL1P5 RNA expression.
This table summarizes DYNLL1P5 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 1. The strongest signals are observed in STAD for RNA.
This table ranks reproducible tumor–normal expression differences for DYNLL1P5. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. DYNLL1P5 shows lower tumor expression in STAD. The STAD box plot shows higher DYNLL1P5 RNA expression in normal versus tumor tissue (log2 FC = −0.146, t-test p = .033).
This table shows molecular features associated with DYNLL1P5 in patient tissues and cancer cell lines. In patient samples, DYNLL1P5 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
